Cancerous disease modifying antibodies
AssigneeArius Research, Inc.
InventorsDavid S. F. Young, Susan E. Hahn
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.
Claims3
An isolated monoclonal antibody or antigen binding fragments thereof encoded by the clone deposited with the ATCC as Accession Number PTA-4829.
The isolated clone deposited with the ATCC as Accession Number PTA-4829.
Dependencies are inferred from the claim text.